The stock of Harvard Bioscience Inc (NASDAQ:HBIO) last traded at $0.47, down -30.32% from the previous session.
HBIO stock price is now 11.30% away from the 50-day moving average and -72.22% away from the 200-day moving average. The market capitalization of the company currently stands at $20.65M.
On March 10, 2023, The Benchmark Company Upgraded its previous ‘Speculative Buy’ rating to ‘Buy’ on the stock increasing its target price from $3 to quote $4, while ‘Northland Capital’ rates the stock as ‘Outperform’
In other news, Green James W, Chief Executive Officer bought 10,000 shares of the company’s stock on Jun 13 ’24. The stock was bought for $29,100 at an average price of $2.91. Upon completion of the transaction, the Chief Executive Officer now directly owns 3,111,091 shares in the company, valued at $1.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06 ’24, Chief Executive Officer Green James W bought 20,000 shares of the business’s stock. A total of $61,400 was incurred on buying the stock at an average price of $3.07. This leaves the insider owning 3,101,091 shares of the company worth $1.46 million. A total of 15.39% of the company’s stock is owned by insiders.
During the past 12 months, Harvard Bioscience Inc has had a low of $0.28 and a high of $3.60. As of last week, the company has a debt-to-equity ratio of 3.01, a current ratio of 0.81, and a quick ratio of 0.40.
The net profit margin was -63.52% and return on equity was -138.80% for HBIO. The company reported revenue of $21.77 million for the quarter, compared to $24.51 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -11.17 percent. For the current quarter, analysts expect HBIO to generate $18.75M in revenue.
